Company Analysis
Sign in

Madrigal Pharmaceuticals, Inc. (MDGL)

Nasdaq: MDGL · Pharmaceutical Preparations · West Conshohocken, PA · filing with the SEC since 2002
Full chart Alerts Compare
Grade5.8
◀ Past 6.2● Present 5.5▶ Future 5.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

187 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Madrigal Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
187
187 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 2 in 2023
Applications published
253
4 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Synta Pharmaceuticals Corp. a former name
US, as the owner printed on each patent
162 granted
180 published
Synta Pharmaceuticals Corp. a former name
named as the applicant on its applications, in US
0 granted
41 published
Madrigal Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
32 published
Madrigal Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
25 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 5, 202512,377,104Methods for treating a fatty liver diseasePharmaceuticalsMadrigal Pharmaceuticals, Inc.
May 21, 202411,986,481Method of synthesizing thyroid hormone analogs and polymorphs thereofPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Nov 7, 202311,806,353Methods of treating liver disorders or lipid disorders with a THR-beta agonistPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Jan 31, 202311,564,926Methods of synthesizing thyroid hormone analogs and polymorphs thereofPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Nov 15, 202211,497,733Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancerPharmaceuticalsSynta Pharmaceuticals Corp.
Nov 8, 202211,491,145Combination therapies comprising targeted therapeuticsPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Jul 5, 202211,377,447Targeted therapeuticsPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Oct 26, 202111,154,538Combination therapy for treatment of ovarian cancerPharmaceuticalsSynta Pharmaceuticals Corp.
Aug 17, 202111,090,308Methods of treating liver disorders or lipid disorders with a THR-beta agonistPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Jan 19, 202110,894,050Methods of synthesizing thyroid hormone analogs and polymorphs thereofPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0368626SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILEPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Aug 7, 20252025/0249011METHODS FOR TREATING A FATTY LIVER DISEASEPharmaceuticalsMadrigal Pharmaceuticals, Inc. · patent 12,377,104 granted from it
May 15, 20252025/0154130NOVEL THR BETA ANALOGS AND USES THEREOFOrganic fine chemistryMadrigal Pharmaceuticals, Inc.
Mar 6, 20252025/0074898SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILEPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Dec 26, 20242024/0423992BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-B AGONISTS AND RELATED USESPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Dec 12, 20242024/0408102RESMETIROM FOR REDUCING LIVER VOLUMEPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Sep 19, 20242024/0307405THERAPEUTIC COMBINATIONS OF ROSUVASTATIN AND RESMETIROM FOR THE TREATMENT OF LIVER DISORDERS OR LIPID DISORDERSPharmaceuticalsMadrigal Pharmaceuticals, Inc.
May 16, 20242024/0156826METHODS OF TREATING LIVER DISORDERS OR LIPID DISORDERS WITH A THR-BETA AGONISTPharmaceuticalsMadrigal Pharmaceuticals, Inc.
May 9, 20242024/0148742METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOFPharmaceuticalsMadrigal Pharmaceuticals, Inc.
Apr 18, 20242024/0122936METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOFPharmaceuticalsMadrigal Pharmaceuticals, Inc. · patent 11,986,481 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 10 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MDGL · research, not advice